SCHEMBL2533381

SCHEMBL2533381

[c]1cccc(N2CCOC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
ALDH1A1 P00352 9/20 0.38
MAPT P10636 7/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
HTT P42858 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
CYP1A2 P05177 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.36
RAD51 Q06609 1/20 0.36
KMO O15229 1/20 0.35
KDM4E B2RXH2 5/20 0.34
HSD17B10 Q99714 4/20 0.34
HPGD P15428 2/20 0.34
ALOX15 P16050 3/20 0.33
MAPK1 P28482 3/20 0.33
PKM P14618 3/20 0.33
TSHR P16473 3/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL159425 0.89 LMNA (0.59) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL20448547 0.83 LMNA (0.52) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL2537667 0.77 LMNA (0.47) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL2218088 0.77 LMNA (0.75) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL29259189 0.75 LMNA (0.79) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL3606736 0.75 L3MBTL1 (0.37) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL541280 0.75 L3MBTL1 (0.41) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL160644 0.73 PRMT6 (0.42) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL1443053 0.73 LMNA (0.47) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL2185093 0.72 MAPT (0.47) LMNAALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044070-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2011-10-25 US disclosed
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE MSD K.K. (JP) 2010-08-19 US disclosed
US-7595316-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-29 US disclosed
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2006-08-10 US disclosed
EP-1642898-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative HRH3, HRH4, HCRTR2 LMNA 3909/4885ALDH1A1 3756/4885MAPT 3841/4885
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE HRH3, HRH4, HRH2 LMNA 3913/4885ALDH1A1 2837/4885MAPT 4280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.